frustrated by his inability to keep an indwelling cannula patent, he had a chance conversation with a colleague who recommended the newly introduced material PTFE (Teflon). Two essential ingredients made the rest of the story possible. The first was his partnership with Wayne Quinton whose technical skill translated Scribner's ideas into practical hardware. The second was his unshakable faith that if he could overcome the technical difficulties he could prolong life in chronic renal failure by long-term haemodialysis. Scarcely another soul in the world shared his faith, but in 12 months he confounded his critics. In May 1985 the Royal Postgraduate Medical School paid its tribute to one of its most famous alumni by conferring on him the Fellowship of the School 25 years after the first successful treatment of chronic renal failure. However, success was not instantaneous. In the early 1960's the trials of haemodialysis for acute renal failure were soon eclipsed by those of dialysis for chronic renal failure. Our faltering start in Newcastle was typical of the time. Excited by Scribner's first reports56 we began to look on every young patient with chronic renal failure as a potential start to the Newcastle programme, but we had no suitable equipment, no space, no staff and no money to get started. One young man dying of renal failure, with a young wife and two small children to support, gave as his occupation "fruit machine operator". We wondered whether the night club owner who employed him could raise the cost of importing a Sweeden Freezer machine and Kiil dialyser from America. He was delighted to do so and set up charity concerts in all his night clubs, to which entertainers willingly gave their services free. In faith we ordered the machine and waited impatiently for the slow boat from Seattle. It arrived too late for our young man and we never saw a penny of the night club money. It was the only time we were let down, for from then on we forgot the rich and appealed to the poor. The ordinary folk of Northern England gave with unbelievable generosity, rivalled only by that of their opposite numbers in Ulster where Mrs Josie Kerr and her colleagues have done so much to support the Belfast Unit. We were left with a big debt and an idle machine, but the latter was soon remedied. A Newcastle trained nurse with renal failure, who lived with her husband in Essex, was given a death sentence and came home to her parents for terminal care. We offered her the dubious privilege of being our first guinea pig and she jumped at it. Like most of the patients of that era she arrived almost in uraemic coma and went through three weeks of psychosis and confusion before pulling through to restored health. After 6 months she was transferred to the care of Dr Stanley Shaldon at the Royal Free Hospital and became Britain's first home dialysis patient. She died after 7 years of bravery in the face of innumerable challenges and vicissitudes, one of the many whose courage kept us going when at times the defects in our treatment seemed so great that it was scarcely worthwhile carrying on. Today the patient of 35 -54 years starting home haemodialysis has a better that 80% chance of surviving 5 years, and the young adult who receives a cadaver graft from haemodialysis or CAPD has a 90% chance of surviving 3 years.7 This is still well below the life expectation of the rest of the population, but it is immensely better than the results recorded in the first two European Registry annual reports8 9 when 40% of patients starting dialysis died in the first six months, 10% of deaths were due to cachexia, 10% of living patients had symptomatic peripheral neuropathy and the average patients received between 2 and 3 litres of blood per month. In this lecture I have tried to pick out the advances in haemodialysis which I believe have contributed most to this transformation of the results in the last 2 decades.
ADVANCES IN HAEMODIALYSIS 1: ACCESS TO THE BLOOD STREAM.
The original Quinton-Scribner all-Teflon shunt was soon displaced by a much more convenient combination of a Teflon tip and a flexible silicon-elastomer (Silastic) tube. The original design had a U-bend under the skin to prevent the transmission of movement to the tip; this design is still in use at Hammersmith today, but in Newcastle we rapidly changed over to a straight tube which was much easier to declot with the help of a nylon tube. We did not routinely use the Ramirez winged modification, designed to improve subcutaneous stability, because it increased the difficulty of removing failed shunts. I am not aware of any controlled study comparing the longevity of these different designs but our clinical impression was that there was little to choose between them, so we chose the simplest and cheapest. For a few patients the shunt was an ideal method of access. My longest lived leg shunt ran for 7 years with one revision of the venous tip and with the arterial site unchanged. For that patient, who did not engage in any rough work and was adept at bathing with one foot out of the water, it was hard to imagine a more convenient system. But for every one like that there were a dozen who suffered for their shunts and dragged down the average survival shown in Table 1. This  table is based on a survey carried out by a Newcastle medical student engaged in a student research project at the time when shunts were being replaced 'by fistulas. She recorded the life history of all shunts and fistulas carried out on the 100 or so patients then on dialysis in Newcastle. Since the majority of fistulas were still functioning and the majority of shunts had failed, a direct life-table analysis of the two methods was not very meaningful. Charting the remaining shunt sites, noting whether the arterial walls felt healthy and whether there were murmurs over the proximal vessels, became part of the routine 6 monthly assessment of dialysis patients. However, the real problem with shunts was the effort required to keep them going. The commonest cause of failure was stenosis of the vein, less commonly of the artery, just proximal to the Teflon tip. At the site of the stenosis, thrombus formed readily, occluding the shunt. Patients were taught to monitor the shunt frequently, examining the colour of the blood in the Silastic tube, or listening over the vein with their stethoscope. Each time a shunt clotted they made a trip by car or ambulance, some of them travelling 100 miles or more to reach the renal unit; sat through an unpleasant declotting session and went home sometimes to find that the shunt had clotted again the same night. Their great salvation was the Cimino-Brescia fistula. Table II shows the results obtained in 1974 in Newcastle. They were not the best in the world, but they were probably the sort of results that were obtained in most British units where one consultant and his rotating registrars shared the task of creating the fistulas. Infection and aneurysm 1 Ligation for heart failure 1 Haemorrhage at each dialysis 1 18
For most patients the radial fistula was the single answer to blood access; it lasted them until their successful transplant and often remained patent to await their return to dialysis if the transplant failed. The radial fistula's long life expectation and relative freedom from complications gives it a long lead over the many alternatives which are rightly used as secondary measures when the fistula fails or cannot be created: proximal fistulas, saphenous loops or straight grafts; expanded PTFE (Gortex) grafts; bovine heterografts; Thomas applique shunts etc. These second and third line measures are required because patients live longer. In 1979 the EDTA-ERA Registry had records of more than 3000 European patients who had survived more than 10 years on renal replacement therapy; about a third had never been transplanted.10 Today there must be several thousand patients in their second decade of haemodialysis; one centre has a 15 year survival of 65 %."1 However, the relatively short survival and the complication rate of all alternatives to the radial fistula justify Dr Lumley's description of vascular access as the Achilles heel of haemodialysis, even in 1984. 12 The difference is that it is now the Achilles heel for a few patients when, in the era of the shunt, nearly every patient fervently wished he had been completely immersed in the Styx. I therefore view as the most hopeful recent development in blood access the increased attention to preserving the radial fistula. had to switch back and forth too frequently for efficiency. Some recirculation inevitably occurred at each switch. This problem was overcome very simply by inserting an expansion chamber into the arterial line. The second problem was harder to overcome; to achieve a high blood flow through the dialyser, the drainage phase had to be fast and therefore the pressure in the dialyser had to be kept high. This produced a high obligatory ultrafiltration. The proportionating machines of the 1970's did not have controlled transmembrane pressure, so the ultrafiltration had to be compensated by saline infusion and the risk of hypotension was considerable. The second problem was elegantly circumvented by the use of a twin -head pump which accelerated the drainage phase and gave the operator complete control over the pressure in the blood compartment; indeed this system permitted the use of high flux dialysers in open circuit for the first time.15 Despite the intermittent flow through the dialyser, its efficiency at a given flow rate per minute was the same as that with a conventional two needle, continuous flow arrangement. '6 Unipuncture proved so popular with patients in Ghent and Newcastle that it was adopted as the standard practice in both centres. However, the extra cost of the twin-head pump has deterred others from using it, and it remains the minority treatment worldwide. The last development has been the marketing of double lumen needles which give a higher flow through the dialyser, and therefore a better dialysis efficiency than tidal flow,'7 provided the fistula is of sufficient size. There were three other measurements that clinicians wanted from the start but which proved much harder to provide: ultrafiltration rate, blood flow rate and presence of air or froth in the venous blood line. The first machine to give a reliable measure of ultrafiltration was the Rhodial,19 designed to curtail ultrafiltration from the high flux RP6 dialyser. It had a closed dialysate compartment from which the ultrafiltrate was displaced into a measuring cylinder. A miniaturised version of this system has been adopted in other machines designed for single-pass dialysis; the dialysate compartment adjacent to the dialyser can be sealed off for a few seconds during which the ultrafiltrate is measured in a small flow meter. Several ingenious devices for continuous measurement of ultrafiltration have been built and a few marketed; they have depended on comparing the inflow to and outflow from the dialyser, which differ by about 0.2-2.0% depending on the ultrafiltration rate. The very precise measurement of flow rate demanded by this exercise has so far defeated the instrument makers. Consequently some machines calculate ultrafiltration rate from the transmembrane pressure, which is computed from pressure measurements at inflow and outflow of both compartments of the dialyser. The final solution of this problem remains a challenge to the designers.
Accurate measurement of blood flow rate is required for research purposes but not for clinical dialysis. Pump speed gives a reasonable measure of blood flow if there is a monitor to detect excessive suction on the arterial line, and bubble transit time over a measured track is an acceptable check. Consequently no manufacturer has made the necessary investment to provide us with a Doppler or similar blood flow meter which is robust and reliable enough for clinic use -a pity because it would be a help in patient care. Detecting air in the venous line, on the other hand is a matter of life and death. However, many British clinicians were slow to adopt air-embolism monitors because they rightly believed that the best way to prevent air embolism was to prevent air entering the circuit, by having all infusion points down stream of the pump. The early monitors, which relied on the creation of an uninterrupted light path in the bubble trap or venous line, were easily fooled by froth. However, it is difficult to eliminate some causes of air embolism such as splits in the blood pump inserts 20 Bergstr6m 's observation has been abundantly confirmed and widely applied in the emergency treatment of fluid overload in both acute and chronic renal failure. Bergstr6m went on to develop the technique of sequential ultrafiltrationhaemodialysis which sought to avoid dialysis hypotension by separating fluid removal from solute removal. There is much anecdotal support for this widely used method, but our own controlled trial failed. to show any advantage over conventional haemodialysis.24 It could be criticised because the patients were unselected, not chosen because of their liability to dialysis hypotension, but I am unaware of any subsequent trial that has overturned the verdict. Whatever the eventual place of sequential ultrafiltration it brought us one great advance. Its use led manufacturers to develop proportioning machines with controlled transmembrane pressure so that the doctor, nurse or home patient can control ultrafiltration at will.
( The Ulster Medical Society, 1985.
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The Ulster Medical Journal ADVANCES IN HAEMODIALYSIS 7: DIALYSER DESIGN. One of the nightmares of the 1960's was building the Kiil dialyser and then waiting on tenterhooks for the air-pressure test that so often signalled a membrane leak and the need to start again from scratch. At the inaugural conference on home dialysis a doctor who was himself a dialysis patient looked at the first proportioning machine with all its monitoring and exclaimed "Don't make me feel like spaceman, just design a dialyser that does not leak". Long after the first man walked on the moon we had coil dialysers with a 10 % leak rate. Today a leak rate of 0.1 % is not exceptional and we owe a great debt to Werner Bandel and his successor at ENKA AG who perfected the manufacture of Cuprophan and first gave us leak-free membranes. One of my privileges since 1970 has been to work with the manufacturers of dialysers, test their products, advise them on design improvements and report the findings to the Department of Health and Social Security who distributed them to renal units. The architect, and often the artisan, of our studies was Dr N A Hoenich whose work has recently been summarised in a DHSS Bulletin. 25 There was a period of excitement and intense activity in the early 1970's reminiscent of the early 1 900's in motor car design or the last decade in computer technology. Small companies sprang up and bright ideas tumbled off the drawing boards in rapid succession. Untroubled by the entanglement of regulation which now emeshes the designer, they experimented freely with new materials and in 3 short years doubled the performance of the artificial kidney. DIY doctors joined in the fun; the most important advance in membrane supports was the work of Dr Holtzenbein who spotted an interesting plastic mesh in the upholstery of his Volkswagen. The pace of advance has slowed, but the need for it has also diminished. Today's dialysers are compact, convenient, reliable and efficient; their cost (corrected for inflation) is about one-twentieth that of the first disposable dialyser. readily reparable telephones on their way to the incinerator because they had been in the home of a dialysis patient, often one who was more certainly free of hepatitis than the telephone engineer who removed them. Specific immune globulin and vaccination against Hepatitis B have removed much of the fear and given our patients once again the freedom to travel abroad on holiday, though sadly the shadow of AIDS now hangs over that newly-found freedom. I welcome the chance to say "Thank you" to the many kind donors who provided holiday homes around Britain and to Mrs Elizabeth Ward who had the imagination to provide hepatitis-free holiday centres in Britain and abroad through the BKPA, for giving our patients the chance of a muchneeded break in the days when fear of hepatitis kept them at home. 
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